Impairment of PI3K/AKT and WNT/β-catenin pathways in bone marrow mesenchymal stem cells isolated from patients with myelodysplastic syndromes

Experimental Hematology

Volumn 44, Issue 1, 2016, Pages 75-83.e4

  Falconi, Giulia ^a   Fabiani, Emiliano ^a   Fianchi, Luana ^a   Criscuolo, Marianna ^a   Raffaelli, Chiara Spertilli ^a   Bellesi, Silvia ^a   Hohaus, Stefan ^a   Voso, Maria Teresa ^b   D'Alò, Francesco ^a   Leone, Giuseppe ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; WNT PROTEIN;

ADULT; AGED; ARTICLE; BONE MARROW DERIVED MESENCHYMAL STEM CELL; CELL ISOLATION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; MALE; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; WNT SIGNALING PATHWAY; BONE MARROW CELL; ENZYMOLOGY; MESENCHYMAL STROMA CELL; METABOLISM; MIDDLE AGED; PATHOLOGY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BETA CATENIN; BONE MARROW CELLS; FEMALE; HUMANS; MALE; MESENCHYMAL STROMAL CELLS; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; WNT PROTEINS;

EID: 84949639305     PISSN: 0301472X     EISSN: 18732399     Source Type: Journal    
DOI: 10.1016/j.exphem.2015.10.005     Document Type: Article

References (30)

1. Bulycheva E., Rauner M., Medyouf H., et al. Myelodysplasia is in the niche: Novel concepts and emerging therapies. Leukemia 2015, 29:259-268.
2. Zhao Z.G., Xu W., Yu H.P., et al. Functional characteristics of mesenchymal stem cells derived from bone marrow of patients with myelodysplastic syndromes. Cancer Lett 2012, 317:136-143.
3. Aanei C.M., Flandrin P., Eloae F.Z., et al. Intrinsic growth deficiencies of mesenchymal stromal cells in myelodysplastic syndromes. Stem Cells Dev 2012, 21:1604-1615.
4. Geyh S., Oz S., Cadeddu R.P., Fröbel J., et al. Insufficient stromal support in MDS results from molecular and functional deficits of mesenchymal stromal cells. Leukemia 2013, 27:1841-1851.
5. Fei C., Zhao Y., Guo J., Gu S., Li X., Chang C. Senescence of bone marrow mesenchymal stromal cells is accompanied by activation of p53/p21 pathway in myelodysplastic syndromes. Eur J Haematol 2014, 93:476-486.
6. Medyouf H., Mossner M., Jann J.C., et al. Myelodysplastic cells in patients reprogram mesenchymal stromal cells to establish a transplantable stem cell niche disease unit. Cell Stem Cell 2014, 14:824-837.
7. Blau O., Baldus C.D., Hofmann W.K., et al. Mesenchymal stromal cells of myelodysplastic syndrome and acute myeloid leukemia patients have distinct genetic abnormalities compared with leukemic blasts. Blood 2011, 118:5583-5592.
8. Fabiani E., Falconi G., Fianchi L., et al. Mutational analysis of bone marrow mesenchymal stromal cells in myeloid malignancies. Exp Hematol 2014, 42:731-733.
9. Poloni A., Maurizi G., Mattiucci D., et al. Overexpression of CDKN2B (p15INK4B) and altered global DNA methylation status in mesenchymal stem cells of high-risk myelodysplastic syndromes. Leukemia 2014, 28:2241-2244.
10. Zhao Y., Wu D., Fei C., et al. Down-regulation of Dicer1 promotes cellular senescence and decreases the differentiation and stem cell-supporting capacities of mesenchymal stromal cells in patients with myelodysplastic syndrome. Haematologica 2015, 100:194-204.
11. Santamaría C., Muntión S., Rosón B., et al. Impaired expression of DICER, DROSHA, SBDS and some microRNAs in mesenchymal stromal cells from myelodysplastic syndrome patients. Haematologica 2012, 97:1218-1224.
12. Raaijmakers M.H., Mukherjee S., Guo S., et al. Bone progenitor dysfunction induces myelodysplasia and secondary leukaemia. Nature 2010, 464:852-857.
13. James A.W. Review of signaling pathways governing MSC osteogenic and adipogenic differentiation. Scientifica 2013, 2013:684736.
14. Trimboli A.J., Cantemir-Stone C.Z., Li F., et al. Pten in stromal fibroblasts suppresses mammary epithelial tumours. Nature 2009, 461:1084-1091.
15. Sun Y., Campisi J., Higano C., et al. Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B. Nat Med 2012, 18:1359-1368.
16. Vardiman J.W., Harris N.L., Brunning R.D. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002, 100:2292-2302.
17. Dominici M., Le Blanc K., Mueller I., et al. Minimal criteria for defining multipotent mesenchymal stromal cells: The International Society for Cellular Therapy position statement. Cytotherapy 2006, 8:315-317.
18. Kim M., Hwang S., Park K., Kim S.Y., Lee Y.K., Lee D.S. Increased expression of interferon signaling genes in the bone marrow microenvironment of myelodysplastic syndromes. PLoS One 2015, 10:e0120602.
19. Chen J., Crawford R., Chen C., Xiao Y. The key regulatory roles of the PI3K/Akt signaling pathway in the functionalities of mesenchymal stem cells and applications in tissue regeneration. Tissue Eng Part B Rev 2013, 19:516-528.
20. McCubrey J.A., Davis N.M., Abrams S.L., et al. Diverse roles of GSK-3: Tumor promoter-tumor suppressor, target in cancer therapy. Adv Biol Regul 2014, 54:176-196.
21. McCubrey J.A., Steelman L.S., Bertrand F.E., et al. Multifaceted roles of GSK-3 and Wnt/β-catenin in hematopoiesis and leukemogenesis: Opportunities for therapeutic intervention. Leukemia 2014, 28:15-33.
22. Boland G.M., Perkins G., Hall D.J., Tuan R.S. Wnt 3a promotes proliferation and suppresses osteogenic differentiation of adult human mesenchymal stem cells. J Cell Biochem 2004, 93:1210-1230.
23. Glass D.A., Bialek P., Ahn J.D., et al. Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev Cell 2005, 8:751-764.
24. Baksh D., Tuan R.S. Canonical and non-canonical Wnts differentially affect the development potential of primary isolate of human bone marrow mesenchymal stem cells. J Cell Physiol 2007, 212:817-826.
25. Pavlaki K., Pontikoglou C.G., Demetriadou A., et al. Impaired proliferative potential of bone marrow mesenchymal stromal cells in patients with myelodysplastic syndromes is associated with abnormal WNT signaling pathway. Stem Cells Dev 2014, 23:1568-1581.
26. Kode A., Manavalan J.S., Mosialou I., et al. Leukaemogenesis induced by an activating β-catenin mutation in osteoblasts. Nature 2014, 506:240-244.
27. Schlegelmilch K., Keller A., Zehe V., et al. WISP 1 is an important survival factor in human mesenchymal stromal cells. Gene 2014, 551:243-254.
28. Akiyama H., Chaboissier M.C., Martin J.F., Schedl A., de Crombrugghe B. The transcription factor Sox9 has essential roles in successive steps of the chondrocyte differentiation pathway and is required for expression of Sox5 and Sox6. Genes Dev 2002, 16:2813-2828.
29. Thiel G., Cibelli G. Regulation of life and death by the zinc finger transcription factor Egr-1. J Cell Physiol 2002, 193:287-292.
30. Spaapen F., van den Akker G.G., Caron M.M., et al. The immediate early gene product EGR1 and polycomb group proteins interact in epigenetic programming during chondrogenesis. PLoS One 2013, 8:e58083.